Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
P3 Health Partners ( (PIII) ) just unveiled an update.
On July 2, 2025, Dr. Sherif Abdou resigned from the Board of Directors of P3 Health Partners Inc., following the conclusion of his transition services agreement on April 30, 2025. Subsequently, the Board appointed Dr. Aric Coffman as a Class I director, with his term set to expire in 2028. Dr. Coffman, who is also the Chief Executive Officer of the company, does not qualify as an independent director and will not serve on any Board committees. He will not receive additional compensation for his role on the Board.
The most recent analyst rating on (PIII) stock is a Buy with a $225.00 price target. To see the full list of analyst forecasts on P3 Health Partners stock, see the PIII Stock Forecast page.
Spark’s Take on PIII Stock
According to Spark, TipRanks’ AI Analyst, PIII is a Neutral.
P3 Health Partners faces financial challenges with negative profitability and high leverage, reflected in its low financial performance score. While technical indicators suggest bearish sentiment, corporate events and earnings call insights show potential for strategic improvements, mitigating some risks.
To see Spark’s full report on PIII stock, click here.
More about P3 Health Partners
Average Trading Volume: 9,148
Technical Sentiment Signal: Sell
Current Market Cap: $46M
For an in-depth examination of PIII stock, go to TipRanks’ Overview page.